文献速递介入腹部USMRCT

基于微泡的肝细胞癌放射增敏:一项II期随机试验的安全性与有效性评估

Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial.
PubMed 文献 · Radiology · 2025-01-01

这项前瞻性II期随机试验于2017年7月至2024年2月纳入98例拟行钇90经动脉放射栓塞的肝细胞癌患者,随机分为联合三次超声触发微泡破坏的治疗组或单纯放射栓塞对照组。结果显示联合治疗安全性相似,客观缓解率提高30个百分点(96% vs 66%,P=0.01),总生存期更高(死亡风险比0.51,95%CI 0.28-0.95,P=0.03)。

要点

  • 联合UTMD组完全或部分缓解率96%(46/48)vs 对照组66%(33/50),提高30个百分点(P=0.01)。
  • 联合UTMD组死亡风险比为0.51(95%CI 0.28-0.95,P=0.03),总生存期高于对照组。
  • 治疗组首次UTMD前后生命体征无差异(所有P≥0.07),两组治疗前后一般实验室值变化无差异(所有P≥0.08)。

核心结论

  • 与单用钇90经动脉放射栓塞相比,联合超声触发微泡破坏进行放射增敏治疗肝细胞癌安全性相似,并改善了治疗反应、延长了生存期。

研究设计与样本

  • 前瞻性II期随机临床试验,2017年7月至2024年2月开展,纳入98例拟行钇90经动脉放射栓塞的肝细胞癌患者,随机分为联合三次超声触发微泡破坏的治疗组(48例)或单纯放射栓塞对照组(50例)。

诊断标准与关键数值

  • 主要终点为采用改良实体瘤疗效评价标准(mRECIST)在MRI或CT上评估的治疗反应;对照组稳定疾病34%(17/50)、部分缓解22%(11/50)、完全缓解44%(22/50),治疗组稳定疾病4%(2/48)、部分缓解35%(17/48)、完全缓解60%(29/48)。

临床应用与阅片要点

  • 本研究为II期随机试验,原文结论为联合超声触发微泡破坏与钇90经动脉放射栓塞相比单用放射栓塞安全性相似,并改善治疗反应、延长生存期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background US contrast agents are gas-filled microbubbles that can be disrupted locally, such as via ultrasound-triggered microbubble destruction (UTMD), which can cause bioeffects that sensitize tumors to radiation. However, the efficacy and safety of UTMD combined with radiation therapy in participants with hepatocellular carcinoma (HCC) are unknown. Purpose To determine the treatment efficacy and safety of UTMD in participants with HCC receiving yttrium 90 (90Y) transarterial radioembolization (TARE). Materials and Methods In this prospective phase II clinical trial conducted from July 2017 to February 2024, participants with HCC scheduled for 90Y-TARE were randomly assigned to undergo 90Y-TARE with three UTMD sessions (treatment group) or 90Y-TARE alone (control group). The primary end point was treatment response evaluated at MRI or CT using modified Response Evaluation Criteria in Solid Tumors. Secondary end points included safety, overall survival, time to next treatment, rate of liver transplantation, and pathologic response in the event of transplantation. Changes in general laboratory values and vital signs were compared using unpaired and paired t tests, survival and time to next treatment between groups were compared between groups using log-rank tests, and treatment response distribution was compared between groups using the Mann-Whitney U test. Results The study sample consisted of 98 participants (mean age, 69 years ± 8.4 [SD]; 71 men). The safety analysis showed no evidence of a difference in vital signs before versus after the initial UTMD session in the treatment group (all P ≥ .07). There was also no evidence of a difference in changes in general laboratory values from before to after treatment between the treatment and control groups (all P ≥ .08). In the control group, 34% (17 of 50) of participants had stable disease, 22% (11 of 50) had partial response, and 44% (22 of 50) had complete response; in the treatment group, 4% (two of 48) had stable disease, 35% (17 of 48) had partial response, and 60% (29 of 48) had complete response. Thus, UTMD increased the proportion of participants who experienced complete or partial response by 30 percentage points (96% [46 of 48] vs 66% [33 of 50]; P = .01). Overall survival was higher in the treatment group than in the control group (mortality hazard ratio, 0.51 [95% CI: 0.28, 0.95]; P = .03). Conclusion Compared with only 90Y-TARE, adding microbubble-based radiosensitization via UTMD to 90Y-TARE in the treatment of HCC had similar safety, provided improved treatment response, and prolonged survival. ClinicalTrials.gov Identifier: NCT03199274 © RSNA, 2025 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Wessner CE, Forsberg F, Lyshchik A, et al. Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial. Radiology. 2025. PMID: 41025990. doi:10.1148/radiol.250083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。